FR2841249A1 - Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 - Google Patents

Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 Download PDF

Info

Publication number
FR2841249A1
FR2841249A1 FR0207542A FR0207542A FR2841249A1 FR 2841249 A1 FR2841249 A1 FR 2841249A1 FR 0207542 A FR0207542 A FR 0207542A FR 0207542 A FR0207542 A FR 0207542A FR 2841249 A1 FR2841249 A1 FR 2841249A1
Authority
FR
France
Prior art keywords
apo
antibody
sep
sample
produced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR0207542A
Other languages
English (en)
French (fr)
Inventor
Jamila Najid
Zouher Majd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit SA filed Critical Genfit SA
Priority to FR0207542A priority Critical patent/FR2841249A1/fr
Priority to EP03748180A priority patent/EP1513878B1/fr
Priority to DE60312513T priority patent/DE60312513T2/de
Priority to DK03748180T priority patent/DK1513878T3/da
Priority to AT03748180T priority patent/ATE356832T1/de
Priority to AU2003267493A priority patent/AU2003267493A1/en
Priority to JP2004514955A priority patent/JP2006515561A/ja
Priority to ES03748180T priority patent/ES2283803T3/es
Priority to CA002489057A priority patent/CA2489057A1/fr
Priority to PCT/FR2003/001888 priority patent/WO2004000884A2/fr
Priority to US10/513,916 priority patent/US20050152900A1/en
Publication of FR2841249A1 publication Critical patent/FR2841249A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Light Receiving Elements (AREA)
FR0207542A 2002-06-19 2002-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100 Pending FR2841249A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0207542A FR2841249A1 (fr) 2002-06-19 2002-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
EP03748180A EP1513878B1 (fr) 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
DE60312513T DE60312513T2 (de) 2002-06-19 2003-06-19 Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100
DK03748180T DK1513878T3 (da) 2002-06-19 2003-06-19 Sammensætninger og fremgangsmåder til analyse af Apo B48 og Apo B100
AT03748180T ATE356832T1 (de) 2002-06-19 2003-06-19 Zusammensetzungen und verfahren zum nachweis vom apo-b48 und apo-b100
AU2003267493A AU2003267493A1 (en) 2002-06-19 2003-06-19 Compositions and methods for apo-b48 and apo-b100 assay
JP2004514955A JP2006515561A (ja) 2002-06-19 2003-06-19 Ａｐｏ−Ｂ４８及びＡｐｏ−Ｂ１００のアッセイのための組成物及び方法
ES03748180T ES2283803T3 (es) 2002-06-19 2003-06-19 Composiciones y procedimientos para la dosificacion de la apo b48 y de la apo b100.
CA002489057A CA2489057A1 (fr) 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
PCT/FR2003/001888 WO2004000884A2 (fr) 2002-06-19 2003-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
US10/513,916 US20050152900A1 (en) 2002-06-19 2003-06-19 Compositions and methods for apo-b48 and apo-b100 assay

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207542A FR2841249A1 (fr) 2002-06-19 2002-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100

Publications (1)

Publication Number Publication Date
FR2841249A1 true FR2841249A1 (fr) 2003-12-26

Family

ID=29719858

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0207542A Pending FR2841249A1 (fr) 2002-06-19 2002-06-19 Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100

Country Status (11)

Country Link
US (1) US20050152900A1 (enExample)
EP (1) EP1513878B1 (enExample)
JP (1) JP2006515561A (enExample)
AT (1) ATE356832T1 (enExample)
AU (1) AU2003267493A1 (enExample)
CA (1) CA2489057A1 (enExample)
DE (1) DE60312513T2 (enExample)
DK (1) DK1513878T3 (enExample)
ES (1) ES2283803T3 (enExample)
FR (1) FR2841249A1 (enExample)
WO (1) WO2004000884A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005093415A1 (ja) * 2004-03-29 2008-02-14 株式会社シバヤギ アポリポタンパク質ｂ−４８の測定方法およびその用途
WO2007058588A1 (en) * 2005-11-18 2007-05-24 T.A.C Thrombosis And Coagulation Aktiebolag Monoclonal antibodies against apolipoprotein m
JP2009531712A (ja) * 2006-03-23 2009-09-03 デ グスマン ブレイヤー、エメリタ アポリポタンパク質フィンガープリント技術
US8088593B2 (en) 2007-10-02 2012-01-03 Theranos, Inc. Modular point-of-care devices, systems, and uses thereof
JP5832723B2 (ja) * 2009-03-06 2015-12-16 協和メデックス株式会社 可溶性インターロイキン−２受容体定量用標準品
EP2408812B1 (en) * 2009-03-17 2015-12-16 CardioVax, LLC Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
RU2013126628A (ru) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм
CA2817543A1 (en) 2010-11-12 2012-06-07 Cedars-Sinai Medical Center Immunomodulatory methods and systems for treatment and/or prevention of hypertension
CN106323875B (zh) 2011-01-21 2019-07-09 西拉诺斯知识产权有限责任公司 样品使用最大化的系统和方法
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US11008628B1 (en) 2013-02-18 2021-05-18 Labrador Diagnostics Llc Systems and methods for analyte testing and laboratory oversight
US10401373B1 (en) 2013-02-18 2019-09-03 Theranos Ip Company, Llc Systems and methods for analyte testing and laboratory oversight
US10422806B1 (en) 2013-07-25 2019-09-24 Theranos Ip Company, Llc Methods for improving assays of biological samples
US11360107B1 (en) 2014-02-25 2022-06-14 Labrador Diagnostics Llc Systems and methods for sample handling
CN106053793A (zh) * 2016-06-20 2016-10-26 诺莱生物医学研究院（北京）有限公司 一种快速检测乳糜血的免疫层析试纸卡及其制备方法
WO2025111449A1 (en) * 2023-11-21 2025-05-30 Sun Diagnostics, Inc. Method and reagent to clear turbidity due to elevated triglycerides in a biological specimen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193926A (ja) * 1984-03-15 1985-10-02 Tokyo Daigaku 単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体
JPS617299A (ja) * 1984-06-20 1986-01-13 Dai Ichi Pure Chem Co Ltd ヒトアポリポ蛋白ｂ４８に高い特異性を有する単クローン性抗体
WO1998056938A1 (en) * 1997-06-13 1998-12-17 Baylor College Of Medicine Lipoproteins as nucleic acid vectors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193926A (ja) * 1984-03-15 1985-10-02 Tokyo Daigaku 単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体
JPS617299A (ja) * 1984-06-20 1986-01-13 Dai Ichi Pure Chem Co Ltd ヒトアポリポ蛋白ｂ４８に高い特異性を有する単クローン性抗体
WO1998056938A1 (en) * 1997-06-13 1998-12-17 Baylor College Of Medicine Lipoproteins as nucleic acid vectors

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHEN, PEI FENG ET AL: "Primary sequence mapping of human apolipoprotein B-100 epitopes. Comparisons of trypsin accessibility and immunoreactivity and implication for apoB conformation", XP002239296, retrieved from STN Database accession no. 109:144839 CA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; INNERARITY, THOMAS L. ET AL: "Structural relationship of human apolipoprotein B48 to apolipoprotein B10", XP002239297, retrieved from STN Database accession no. 108:126927 CA *
DATABASE WPI 1985 Derwent World Patents Index; AN 1985-285482, XP002239299, "monoclonal antibody against human apolipoprotein 100 produced by hybridoma created by fusion of mouse spleen and myeloma cells" *
DATABASE WPI 1986 Derwent World Patents Index; AN 1986-052892, XP002239298, "Monoclonal antibody has high specificity against human apolipoprotein 48" *
EUROPEAN JOURNAL OF BIOCHEMISTRY (1988), 175(1), 111-18, 1988 *
JOURNAL OF CLINICAL INVESTIGATION (1987), 80(6), 1794-8, 1987 *

Also Published As

Publication number Publication date
WO2004000884A2 (fr) 2003-12-31
DE60312513D1 (de) 2007-04-26
ES2283803T3 (es) 2007-11-01
ATE356832T1 (de) 2007-04-15
DK1513878T3 (da) 2007-07-16
AU2003267493A1 (en) 2004-01-06
US20050152900A1 (en) 2005-07-14
DE60312513T2 (de) 2007-12-06
CA2489057A1 (fr) 2003-12-31
EP1513878A2 (fr) 2005-03-16
EP1513878B1 (fr) 2007-03-14
JP2006515561A (ja) 2006-06-01
WO2004000884A3 (fr) 2004-04-08

Similar Documents

Publication Publication Date Title
EP1513878B1 (fr) Compositions et methodes pour le dosage de l'apo b48 et de l'apo b100
EP1527101B1 (fr) Anticorps specifiques du probnp(1-108) et leur utilisation pour le diagnostic de l'insuffisance cardiaque
HUE028331T2 (en) N-11 truncated β-amyloid monoclonal antibody, preparation, method and use
WO1994004563A1 (fr) PEPTIDES CONTENANT DES SEQUENCES D'ACIDES AMINES RESPECTIVES SELECTIONNEES PARMI CELLES DE LA LIPOPROTEINE(a) ET DE L'APOLIPOPROTEINE(a), ANTICORPS RECONNAISSANT CES SEQUENCES D'ACIDES AMINES ET PROCEDE D'ANALYSE UTILISANT CES ANTICORPS
WO1990006371A1 (fr) ANTICORPS MONOCLONAUX ANTI-INTERLEUKINES 1α ET 1β, LEUR PROCEDE DE PRODUCTION ET APPLICATIONS DESDITS ANTICORPS A LA DETECTION DES INTERLEUKINES 1α et 1β ET EN THERAPEUTIQUE
CA2274776C (en) Method for analyzing annexin v in urine and use thereof
EP2446038B1 (fr) Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine
EP1423707B1 (fr) Methodes de criblage de molecules utiles pour la prevention des maladies cardiovasculaires
JP2023516171A (ja) ＡＤＭ－Ｇｌｙ／バイオＡＤＭ比が閾値を超える患者においてＡＤＭ－ＧｌｙからバイオＡＤＭへの転移を促進するための遊離Ｎ末端に結合する抗ＡＤＭ抗体およびビタミンＣとの組合せ
EP0327418B1 (fr) Procédé immunométrique pour le dosage de particules de lipoprotéine, anticorps monoclonaux anti-Lp(a) et application au diagnostic de l'athérosclérose
JP3018110B2 (ja) モノクローナル抗体
JPH1090268A (ja) 免疫学的粒子凝集反応方法
EP0667897B1 (fr) Methode d'immunodosage specifique de la glutathion peroxydase plasmatique humaine
EP1423708B1 (fr) Compositions et methodes pour le dosage de l'aa4rp
JPH0216997A (ja) γ−ＡＮＰを認識するモノクローナル抗体
JP2005502029A (ja) アポｂおよび非アポｂ含有粒子中のアポｃｉｉｉを測定する新規な方法
JPH0257177A (ja) モノクローナル抗体産生細胞ラインおよびモノクローナル抗体
KR0135708B1 (ko) 인간 혈중 아포지단백질 비-100(b-100)에 대한 신규 단일클론 항체 및 이들의 생산을 위한 재조합 하이브리도마 세포주
Najib Compositions and methods for apo-b48 and apo-b100 assay
FR2843395A1 (fr) Composition et methodes pour le dosage de l'aa4rp
JP2775445B2 (ja) 抗フェニトインモノクローナル抗体及びそれを産生するハイブリドーマ
JPH0257178A (ja) モノクローナル抗体産生細胞ラインおよびモノクローナル抗体